Company news
Calidi Biotherapeutics, Inc. (AMEX:CLDI) news
Every Calidi Biotherapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026
June 8, 2026
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
May 26, 2026
Calidi Biotherapeutics Provides Required NYSE American Disclosure
May 22, 2026
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
May 14, 2026
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Us...
April 29, 2026
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
April 21, 2026
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TR...
April 20, 2026
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical ...
April 15, 2026
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Pla...
April 14, 2026
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s A...
April 7, 2026
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
April 2, 2026
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting ...
April 1, 2026
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
March 27, 2026
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation ...
March 24, 2026
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA...
March 12, 2026
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment O...
March 9, 2026
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
March 6, 2026
Calidi Biotherapeutics Announces Proposed Public Offering
March 5, 2026
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AAC...
February 20, 2026
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking...
February 12, 2026
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
January 28, 2026
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
November 17, 2025
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
November 13, 2025
Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor D...
November 10, 2025
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
November 4, 2025
Matica Bio, a CDMO Leader in Oncolytic Virus Manufacturing, Partners with Calidi Biotherapeutics to Advance Calidi's Project Toward IND
November 3, 2025
Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
October 30, 2025
Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Pla...
October 22, 2025
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
September 29, 2025
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment O...
August 21, 2025
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
August 20, 2025
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
August 8, 2025
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for t...
July 29, 2025
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
July 25, 2025
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
July 22, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
July 10, 2025
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
July 9, 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
July 8, 2025
Calidi Biotherapeutics Announces Shareholder Letter from CEO
June 27, 2025
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual M...
June 2, 2025
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
May 14, 2025
Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR An...
April 28, 2025
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711
April 25, 2025
Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
April 23, 2025
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
April 22, 2025